<DOC>
	<DOC>NCT02633943</DOC>
	<brief_summary>This is a multi-center, long-term safety and efficacy follow-up study for subjects with hemoglobinopathies (Î²-thalassemia or severe sickle cell disease) who have been treated with ex vivo gene therapy drug product in bluebird bio-sponsored clinical studies. After completing the parent clinical study (approximately 2 years), eligible subjects will be followed for an additional 13 years for a total of 15 years post-drug product infusion. No investigational drug product will be administered in the study.</brief_summary>
	<brief_title>Longterm Follow-up of Subjects With Hemoglobinopathies Treated With Ex Vivo Gene Therapy</brief_title>
	<detailed_description />
	<mesh_term>Anemia, Sickle Cell</mesh_term>
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>Hemoglobinopathies</mesh_term>
	<mesh_term>beta-Thalassemia</mesh_term>
	<criteria>Provision of written informed consent for this study by subjects, or as applicable, subject's parent(s)/legal guardian(s) Treated with drug product for therapy of a hemoglobinopathy in a bluebird biosponsored clinical study Able to comply with study requirements Met the VCN discontinuation criterion in the parent study</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>